US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

SGMO Sangamo Therapeutics Inc

0.4994

-0.0405 (-7.50%)

Última actualización: 12:51:17

Retrasado por 15 minutos

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Haga Click aquí para más Gráficas Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De May 2023 a May 2024

Haga Click aquí para más Gráficas Sangamo Therapeutics.

Noticias sobre Sangamo Therapeutics Inc SGMO

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Jueves 2 de Mayo 2024 (6 días hace) • Business Wire

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Lunes 22 de Abril 2024 (2 semanas hace) • Business Wire

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Viernes 22 de Marzo 2024 (2 meses hace) • Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Miércoles 13 de Marzo 2024 (2 meses hace) • Business Wire

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Miércoles 13 de Marzo 2024 (2 meses hace) • Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Martes 12 de Marzo 2024 (2 meses hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Martes 27 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 27 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 27 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 27 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 27 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Lunes 12 de Febrero 2024 (3 meses hace) • Business Wire

Más de Sangamo Therapeutics Inc Artículos de Noticias

Health Care Select Sector

American Express

Financial Select Sector

Euro vs US Dollar

Verizon Communications

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones